Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Cash Flow: 2016-2024

Historic Net Cash Flow for Dianthus Therapeutics (DNTH) over the last 9 years, with Dec 2024 value amounting to -$109.4 million.

  • Dianthus Therapeutics' Net Cash Flow rose 115.23% to $42.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.3 million, marking a year-over-year increase of 118.02%. This contributed to the annual value of -$109.4 million for FY2024, which is 193.50% down from last year.
  • Latest data reveals that Dianthus Therapeutics reported Net Cash Flow of -$109.4 million as of FY2024, which was down 193.50% from $117.0 million recorded in FY2023.
  • Dianthus Therapeutics' Net Cash Flow's 5-year high stood at $117.0 million during FY2023, with a 5-year trough of -$109.4 million in FY2024.
  • Over the past 3 years, Dianthus Therapeutics' median Net Cash Flow value was $7.8 million (recorded in 2022), while the average stood at $5.1 million.
  • Per our database at Business Quant, Dianthus Therapeutics' Net Cash Flow tumbled by 202.87% in 2020 and then skyrocketed by 1,402.07% in 2023.
  • Dianthus Therapeutics' Net Cash Flow (Yearly) stood at -$6.9 million in 2020, then soared by 1,162.26% to $73.5 million in 2021, then crashed by 89.41% to $7.8 million in 2022, then skyrocketed by 1,402.07% to $117.0 million in 2023, then slumped by 193.50% to -$109.4 million in 2024.